NCT04430738 2026-02-24
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
Seagen Inc.
Phase 2 Active not recruiting
Clinical Trials
184 trialsNCT06501989 2026-02-11
Study of 5-fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancer
Inova Health Care Services
Phase 2 Withdrawn
NCT00556413 2026-02-05
Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 2 Completed
NCT06948448 2026-01-21
A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer
Ono Pharmaceutical Co. Ltd
Phase 2 Recruiting
NCT06792695 2026-01-20
CANTOR
AstraZeneca
Phase 2 Recruiting
NCT00335816 2026-01-14
Radiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT03366155 2026-01-08
Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT05959356 2025-12-17
CEIL
Sun Yat-sen University
Phase 2 Recruiting
NCT03984578 2025-11-18
Window of Opportunity Study in Colorectal Cancer
National Cancer Centre, Singapore
Phase 2 Completed
NCT05382442 2025-10-14
A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer
Akeso
Phase 2 Active not recruiting
NCT03929666 2025-09-12
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Jazz Pharmaceuticals
Phase 2 Completed
NCT05678257 2025-09-12
A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer
NuCana plc
Phase 2 Terminated
NCT00766142 2025-08-29
COCHISE
Institut Bergonié
Phase 2 Terminated
NCT00492999 2025-08-17
Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT03493048 2025-08-03
Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM
Sun Yat-sen University
Phase 2 Active not recruiting
NCT05571644 2025-07-23
OPTICAL-2
Sun Yat-sen University
Phase 2 Recruiting
NCT05489211 2025-07-11
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
AstraZeneca
Phase 2 Recruiting
NCT05330429 2025-07-01
ELEVATE CRC
Gilead Sciences
Phase 2 Terminated
NCT04245865 2025-04-27
Toco-CoR
Vejle Hospital
Phase 2 Active not recruiting
NCT05004350 2025-04-15
NAUTICALCRC
Pierre Fabre Medicament
Phase 2 Completed
NCT04072198 2025-03-13
NIVACOR
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 2 Completed
NCT01652196 2025-02-05
Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT04513951 2025-01-09
AVETRIC
Gruppo Oncologico del Nord-Ovest
Phase 2 Completed
NCT06493760 2024-09-19
A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 2 Recruiting
NCT02705300 2024-08-29
Side Effects to FOLFOXIRI + Tocotrienol/Placebo as First Line Treatment of Metastatic Colorectal Cancer
Vejle Hospital
Phase 2 Completed
NCT06341296 2024-08-12
Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer
West China Hospital
Phase 2 Recruiting
NCT00321828 2024-03-21
Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colon Cancer That Cannot Be Removed By Surgery
NSABP Foundation Inc
Phase 2 Completed
NCT03698461 2024-01-31
CLIMB
Asan Medical Center
Phase 2 Completed
NCT04034459 2023-11-14
AIO-KRK-0116
Ludwig-Maximilians - University of Munich
Phase 2 Unknown
NCT04310176 2023-11-13
REVOLUTION
National Cancer Institute, Naples
Phase 2 Unknown
NCT00601198 2023-08-01
A Study of Amifostine (Ethyol) in Patients With Colorectal Cancer
University of Cincinnati
Phase 2 Terminated
NCT00098787 2023-07-05
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT01328171 2023-06-15
VOLFI
AIO-Studien-gGmbH
Phase 2 Completed
NCT01991873 2023-06-15
PanaMa
AIO-Studien-gGmbH
Phase 2 Completed
NCT03279289 2023-04-13
AFEMA
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Phase 2 Completed
NCT01628211 2023-03-24
HIPEC
National Cancer Institute, Naples
Phase 2 Unknown
NCT05733000 2023-03-10
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
Northwestern University
Phase 2 Recruiting
NCT05480280 2023-02-28
FIND
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2 Unknown
NCT00936832 2022-08-30
Sunitinib Malate and Combination Chemotherapy as Front-Line Therapy in Treating Patients With Metastatic Rectal Cancer That Cannot Be Removed by Surgery
Federation Francophone de Cancerologie Digestive
Phase 2 Withdrawn
NCT04425239 2022-04-07
IMPROVE
National Cancer Institute, Naples
Phase 2 Completed
NCT04247984 2022-03-11
A Comparison of mXELIRI Regimen and FOLFIRI Combined Bevacizumab Regimen as First-line Chemotherapy Regimen for Metastatic Colorectal Cancer
ChineseAMS
Phase 2 Completed
NCT03099486 2022-02-07
Regorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression in mCRC
Fox Chase Cancer Center
Phase 2 Terminated
NCT03050814 2021-12-20
Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00308516 2021-12-10
5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT04430985 2021-10-27
IMMUNOX
Herlev Hospital
Phase 2 Withdrawn
NCT00803647 2021-10-06
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
NSABP Foundation Inc
Phase 2 Completed
NCT00640081 2021-09-22
Combination Chemotherapy and Cetuximab as First-Line Therapy in Treating Patients With Advanced and/or Metastatic Colorectal Cancer
Medical Research Council
Phase 2 Completed
NCT02414009 2021-09-09
CAPTEM
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Completed
NCT03142516 2021-06-21
OPALO
Grupo Espanol Multidisciplinario del Cancer Digestivo
Phase 2 Completed
NCT01442935 2021-06-18
Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases
UNICANCER
Phase 2 Completed